NCT02736656
Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)
StatusActive, Not Recruiting
PhasePhase 3
Primary completion (estimated)
At risk: Primary completion moved at least 2 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 11 versions: 11 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 23 words Show 4 more changesShow less
- Primary and study completion pushed from Sep 2026 to Dec 2026
- Secondary endpoints: details revised at 1 of 2 entries
- Site details revised at 2 of 16 sites
- Publications: details revised at 1 of 1 entry
- Minor Study description expanded, about 12 wordsv10
- Notable Eligibility criteria expanded, about 191 words
- Secondary endpoints revised (2)
- Study description expanded, about 9 words
Notable Primary and study completion dates: Jun 2025 to Sep 2026v8 Show 4 more changesShow less
- Eligibility criteria expanded, about 35 words
- Enrollment target: 1200 to 1400
- Study description shortened, about 23 words
- Study title revised
- Notable Primary and study completion dates: Jun 2024 to Jun 2025v7
Show 5 earlier versionsHide 5 earlier versions
- Minor Interventions: SPN-812 ER (Drug) to SPN-812 (Drug)v6
- Notable Primary and study completion dates: Jun 2021 to Jun 2024
- Eligibility criteria expanded, about 117 words
- Secondary endpoints revised (2)
- Study description expanded, about 11 words
- Minor Trial status: Recruiting to Active, Not Recruiting
- Secondary endpoints: details revised at 1 of 2 entries
- Site details revised at 16 of 16 sites
Notable Enrollment target: 200 to 1200v3 Show 6 more changesShow less
- Primary and study completion dates: Apr 2019 to Jun 2021
- Eligibility criteria revised
- Study sites: 1 to 16
- Start date: Apr 2016 to Feb 2, 2016
- Secondary endpoints revised (2)
- Study description expanded, about 130 words
- Notable Trial status: Not Yet Recruiting to Recruiting
- Eligibility criteria expanded, about 4 words
- Study sites: 0 to 1
- Study title expanded, about 2 words
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Incidence of adverse events
Timeframe: up to 72 months
Secondary (2)
Trends in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHD-RS-IV-Preschool, ADHD-RS-IV or ADHD-RS-5) Score
Trends in Clinical Global Impression-Improvement (CGI-I) scale score
Arms and interventions
Open-Label TreatmentExperimental
Cohort 'A': Children and adolescents, 6-17 years of age, who completed a Phase 2 (Study 812P202) or Phase 3 (Study 812P301, 812P302, 812P303, or 812P304) randomized, double-blind, placebo-controlled clinical trial. Cohort 'B': Preschool-age children, 4-5 years of age, who completed a Phase 4 (Study 812P401) randomized, double-blind, placebo-controlled clinical trial.
Drugs: SPN-812
Sites
16 sites in 1 country